Phase 2 Study of Olutasidenib with Hypomethylating Agents in IDH1-mutated Hematologic Malignancies
A Phase 2 study is evaluating the efficacy and safety of olutasidenib in combination with hypomethylating agents in patients with IDH1-mutated higher-risk myelodysplastic syndromes, chronic myelomonocytic leukemia, or advanced myeloproliferative neoplasms.